Log in to your Inderes Free account to see all free content on this page.

Lundbeck

37.46 DKK

+1.30 %

Less than 1K followers

HLUN B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+1.30 %

-12.07 %

-13.21 %

-18.74 %

+9.21 %

-16.50 %

+44.08 %

-25.67 %

+52.28 %

Lundbeck is a pharmaceutical company. The greatest focus is found in research on psychiatric and neurotic disorders, which includes the treatment of depression, schizophrenia, Alzheimer's and Parkinson's syndrome. The company conducts research, development and distribution of medicines where the customer base can be found on a global level. The company was originally founded in 1915 and has its headquarters in Valby.

Market cap

37.3B DKK

Turnover

43.25M DKK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

18.3.

2026

General meeting '26

19.3.

2026

Annual dividend

13.5.

2026

Interim report Q1'26

All

Press releases

ShowingAll content types

Regulatory press releaseyesterday

H. Lundbeck A/S: Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

Regulatory press release2/4/2026, 6:13 PM

H. Lundbeck A/S: Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

Regulatory press release2/4/2026, 6:50 AM

H. Lundbeck A/S: Lundbeck Annual Report 2025

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release2/4/2026, 6:30 AM

H. Lundbeck A/S: Record 2025 performance with revenue up 13% CER and adjusted EBITDA up 24% CER positions Lundbeck for continued growth in 2026

Press release1/30/2026, 2:00 PM

H. Lundbeck A/S: Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® (eptinezumab), at HCOP Annual Conference

Regulatory press release12/8/2025, 7:22 AM

H. Lundbeck A/S: Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

Press release12/6/2025, 5:00 PM

H. Lundbeck A/S: Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting

Press release12/2/2025, 7:00 AM

H. Lundbeck A/S: Lundbeck to present comprehensive new bexicaserin dataset in patients with rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting

Regulatory press release11/26/2025, 4:23 PM

H. Lundbeck A/S: ANNOUNCEMENT FOR THE PURPOSES OF ARTICLE 17 "MAR" RULES (EU) NO. 596/2014 (INSIDE INFORMATION) AND RULE 2.8 OF THE IRISH TAKEOVER PANEL ACT 1997, TAKEOVER RULES, 2022 (THE "IRISH TAKEOVER RULES")

Regulatory press release11/14/2025, 11:44 AM

H. Lundbeck A/S: ANNOUNCEMENT FOR THE PURPOSES OF RULE 2.12 OF THE IRISH TAKEOVER PANEL ACT 1997, TAKEOVER RULES, 2022 (THE "IRISH TAKEOVER RULES") AND MAR ARTICLE 17 (INSIDE INFORMATION)

Press release11/14/2025, 7:55 AM

H. Lundbeck A/S: Lundbeck files for marketing authorization across key Asian markets for Vyepti® (eptinezumab) for the preventive treatment of migraine

Regulatory press release11/11/2025, 2:34 PM

H. Lundbeck A/S: Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti[®] and Rexulti[®] driven by additional investments

Regulatory press release11/11/2025, 2:21 PM

H. Lundbeck A/S: Lundbeck raises financial guidance for 2025

Press release10/27/2025, 8:00 AM

H. Lundbeck A/S: Lundbeck and OpenAI join forces to unlock innovation and boost productivity

Press release10/20/2025, 7:00 AM

H. Lundbeck A/S: Lundbeck and Contera Pharma announce research collaboration to advance RNA-targeting medicines for serious neurological conditions

Press release10/13/2025, 6:00 AM

H. Lundbeck A/S: Lundbeck's bexicaserin receives Breakthrough Therapy Designation in China for the treatment of seizures in severe rare epilepsies

Press release10/2/2025, 7:00 AM

H. Lundbeck A/S: Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025

Regulatory press release9/20/2025, 6:00 AM

H. Lundbeck A/S: Otsuka and Lundbeck receive Complete Response Letter from U.S. FDA for sNDA of REXULTI® (brexpiprazole) in combination with sertraline for the treatment of adults with PTSD

Press release9/11/2025, 6:00 AM

H. Lundbeck A/S: Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine

Press release9/9/2025, 12:30 PM

H. Lundbeck A/S: Lundbeck sharpens commercial focus in line with strategy, initiates partnering in 27 markets by end-2025

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.